期刊
BIOMATERIALS
卷 34, 期 26, 页码 6249-6260出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2013.04.065
关键词
cRGDfK-lipopeptide; Tumor vasculature targeting; Integrin mediated transfection; Integrin receptor selectivity
资金
- Council of Scientific and Industrial Research, Government of India, New Delhi [NWP-0036, CSC-0302]
- Council of Scientific and Industrial Research, Government of India, New Delhi
Ever since the finding that alpha v beta 3 integrin receptors are over expressed on the endothelial cell surfaces of tumor vasculatures relative to normal resting vasculatures was disclosed in 1994, alpha v beta 3 integrin receptor selective systems are finding increasing applications both for targeting anti-cancer drugs/genes selectively to tumor vasculatures and for imaging growing tumors. Among the cyclic peptide based integrin antagonists identified through both phage display and structure-activity studies, mainly alpha v beta 3 integrin selective cyclic peptide c(RGDfK-) has found most widespread exploitations for targeting chemotherapeutic drugs/genes to both tumor and tumor vasculatures in anti-angiogenic cancer therapy. Herein we show that a lipopeptide containing widely acclaimed alpha v beta 3 integrin receptor selective cyclic RGDfK ligand in its head-group area can effectively deliver genes into both the endothelial and tumor cells via all the three widely used integrin receptors namely alpha v beta 3, alpha v beta 5 & alpha 5 beta 1 integrins. We demonstrate that intravenous administration of the electrostatic complex of the cationic liposomes of an amphiphiles with cyclic RGDfK head-group and the anti-cancer p53 gene leads to significant tumor growth inhibition in a syngeneic mouse tumor model presumably through inducing apoptosis of tumor neovasculatures. The findings delineated herein provide experimental evidence that cyclic-RGDfK-ligand may not be that highly selective for alpha v beta 3 integrin receptor as is popularly believed. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据